WASHINGTON, May 22 (TNSLrpt) -- The U.S. Department of Labor's Bureau of Labor Statistics issued the following report (No. USDL-25-0849) on May 21, 2025, entitled "State Employment and Unemployment - April 2025": * * * Unemployment rates were higher in April in 3 states and the District of Columbia, lower in 2 states, and stable in 45 states, the U.S. Bureau of Labor Statistics reported today. Twenty-six states and the District had jobless rate increases from a year earlier, 1 state had a decr  more

WASHINGTON, May 21 -- The U.S. Department of Homeland Security Federal Emergency Management Agency issued the following news release: * * * DHS Makes $360 Million Available to Communities to Increase Number of Trained Firefighters and Keep Communities Safe Additional $36 Million to be Made Available for Research to Improve Firefighter Health and Safety WASHINGTON - Under the leadership of President Trump, states and localities will be empowered to manage disasters and emergencies. These fire  more

WASHINGTON, May 21 -- The U.S. Department of Homeland Security issued the following news release: * * * DHS Sets the Record Straight on Media Frenzy over Deportation Flights for Worst of the Worst Including Murderers, Rapists, and Pedophiles President Trump and Secretary Noem are working every day to get vicious criminals out of our country while activist judges are fighting to bring them back onto American soil WASHINGTON - The Department of Homeland Security today hosted a press conferenc  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * To: General Counsel Amphastar Pharmaceuticals Inc. 11570 6th Street Rancho Cucamonga, CA 91730 brianm@amphastar.com Re: Improper Orange Book Patent Listing for Baqsimi Dear Counsel, I write regarding Amphastar Pharmaceuticals Inc.'s ("Amphastar") ongoing obligation to ensure the propriety of its patent listings in the FDA's Approved Drug Products with T  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * To: Andrew Teehan, General Counsel, Covis Pharma GMBH, 200 Connell Dr. Berkeley Heights, New Jersey 07922, ateehan@covispharma.com Re: Improper Orange Book Patent Listings for Tudorza Pressair and Duaklir Pressair Dear Mr. Teehan, I write regarding Covis Pharma GMBH's ("Covis") ongoing obligation to ensure the propriety of its patent listings in the FDA's Appro  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * To: Mylan Specialty LP Attn: Legal Counsel Corporation Service Co. 251 Little Falls Dr. Wilmington, New Castle, DE 19808 * Brian Roman Global General Counsel Viatris Inc. 1000 Mylan Blvd. Canonsburg, PA 15322 Brian.Roman@viatris.com * * * Re: Improper Orange Book Patent Listings for EPIPEN and EPIPEN Jr. Dear Mr. Roman: I write regarding Mylan Speci  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * To: Norton (Waterford) Limited Attn: Legal Counsel Waterford Industrial Park Unit 301, Cork Rd Waterford, X91 WK68, Ireland * Brian Savage, SVP and General Counsel Global Litigation, Teva Pharmaceuticals USA, Inc. 400 Interpace Pkwy, Suite 3 Parsippany, NJ 07054 brian.savage@tevapharm.com * * * Re: Improper Orange Book Patent Listings for QVAR RediHale  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * To: Elizabeth McGee General Counsel Novartis Pharmaceuticals Corp. 1 Health Plaza, East Hanover, New Jersey 07936 Elizabeth.mcgee@novartis.com Re: Improper Orange Book Patent Listings for Seebri and Utibron Dear Ms. McGee, I write regarding Novartis Pharmaceuticals Corp.'s ("Novartis") ongoing obligation to ensure the propriety of its patent listings in  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * Teva Branded Pharmaceutical Products R&D, Inc. Attn: Legal Counsel c/o Corporate Creations Network Inc. 3411 Silverside Road Tatnall Building, Ste. 104 Wilmington, New Castle, DE 19810 * Brian Savage, SVP and General Counsel Global Litigation, Teva Pharmaceuticals USA, Inc. 400 Interpace Pkwy, Suite 3 Parsippany, NJ 07054 brian.savage@tevapharm.com * *  more

WASHINGTON, May 22 -- The Federal Trade Commission Bureau of Competition issued the following warning letter on May 21, 2025: * * * To: David R. McAvoy Chief Legal Officer Teva Pharmaceutical Industries Ltd. c/o Teva Pharmaceuticals USA, Inc. 400 Interpace Pkwy, Suite 3 Parsippany, NJ 07054 * Brian Savage, SVP and General Counsel Global Litigation Teva Pharmaceuticals USA, Inc. 400 Interpace Pkwy, Suite 3 Parsippany, NJ 07054 brian.savage@tevapharm.com * * * Re: Improper Orange B  more